Pimavanserin tartrate + Placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Alzheimer's Disease Psychosis
Conditions
Alzheimer's Disease Psychosis
Trial Timeline
Nov 1, 2013 → Oct 27, 2016
NCT ID
NCT02035553About Pimavanserin tartrate + Placebo
Pimavanserin tartrate + Placebo is a phase 2 stage product being developed by Acadia Pharmaceuticals for Alzheimer's Disease Psychosis. The current trial status is completed. This product is registered under clinical trial identifier NCT02035553. Target conditions include Alzheimer's Disease Psychosis.
What happened to similar drugs?
20 of 20 similar drugs in Alzheimer's Disease Psychosis were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02035553 | Phase 2 | Completed |
| NCT01174004 | Phase 3 | Completed |
Competing Products
20 competing products in Alzheimer's Disease Psychosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LY450139 + Placebo | Eli Lilly | Phase 3 | 40 |
| Solanezumab + Placebo | Eli Lilly | Phase 3 | 32 |
| LY450139 dihydrate + placebo | Eli Lilly | Phase 2 | 35 |
| GSK4527226 | Alector | Phase 2 | 29 |
| GSK4527226 | Alector | Phase 2 | 32 |
| AL002 | Alector | Phase 2 | 17 |
| Solanezumab + Placebo | Eli Lilly | Phase 3 | 32 |
| simufilam | Cassava Sciences | Phase 2 | 17 |
| Remternetug + Placebo | Eli Lilly | Phase 3 | 44 |
| solanezumab | Eli Lilly | Phase 2 | 35 |
| LY2886721 + Placebo | Eli Lilly | Phase 1 | 29 |
| Gantenerumab + Gantenerumab + Gantenerumab + Placebo | Chugai Pharmaceutical | Phase 1 | 29 |
| Alfoatirin® Tab. + Aripezil® Tab. + Aripezil® Tab. | Yuhan | Approved | 39 |
| FK962 | Astellas Pharma | Phase 2 | 27 |
| ASP0777 + Placebo | Astellas Pharma | Phase 1 | 29 |
| Elenbecestat + Placebo | Eisai | Phase 3 | 32 |
| Donepezil | Eisai | Approved | 43 |
| Aricept (donepezil SR 23 mg) + Aricept (donepezil IR 10 mg) | Eisai | Phase 3 | 40 |
| Donepezil hydrochloride | Eisai | Phase 3 | 40 |
| Donepezil Hydrochloride | Eisai | Pre-clinical | 26 |